Mar. Drugs 2013, 11(9), 3324-3334; doi:10.3390/md11093324
Article

The Effect of Low-Dose Marine n-3 Fatty Acids on Plasma Levels of sCD36 in Overweight Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial

1 Department of Cardiology, Center for Cardiovascular Research, Aalborg University Hospital, Aalborg 9000, Denmark 2 Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg 9000, Denmark
* Author to whom correspondence should be addressed.
Received: 13 June 2013; in revised form: 1 August 2013 / Accepted: 8 August 2013 / Published: 30 August 2013
(This article belongs to the Special Issue Marine Fatty Acids)
PDF Full-text Download PDF Full-Text [508 KB, uploaded 30 August 2013 11:42 CEST]
Abstract: CD36 is a scavenger receptor involved in lipid uptake and inflammation. Recently, non-cell-bound CD36 (sCD36) was identified in plasma and suggested to be a marker of lipid accumulation in the vessel wall. Marine n-3 polyunsaturated fatty acids (PUFA) may have cardioprotective effects. This study evaluated the effect of marine n-3 PUFA on sCD36 levels in overweight subjects. Fifty overweight subjects were randomized to 1.1 g of n-3 PUFA or 2 g of olive oil daily for six weeks. Neutrophils were isolated at baseline and after six weeks of treatment while an adipose tissue biopsy was obtained at baseline. The content of n-3 PUFA in adipose tissue and neutrophils was analyzed by gas chromatography, while plasma levels of sCD36 were determined using an enzyme-linked immunosorbent assay (ELISA). After six weeks of supplement plasma sCD36 did not differ between supplements (P = 0.18). There was no significant correlation between plasma sCD36 levels and n-3 PUFA in neutrophils at baseline (r = −0.02, P = 0.88), after six weeks supplement (r = −0.03, P = 0.85) or in adipose tissue (r = 0.14, P = 0.34). This study therefore does not provide evidence for a cardioprotective effect of n-3 PUFA acting through a CD36-dependent mechanism.
Keywords: n-3 PUFA; CD36; adipose tissue; cardiovascular disease; randomised controlled trial

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Venø, S.K.; Nielsen, M.R.S.; Lundbye-Christensen, S.; Schmidt, E.B.; Handberg, A. The Effect of Low-Dose Marine n-3 Fatty Acids on Plasma Levels of sCD36 in Overweight Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial. Mar. Drugs 2013, 11, 3324-3334.

AMA Style

Venø SK, Nielsen MRS, Lundbye-Christensen S, Schmidt EB, Handberg A. The Effect of Low-Dose Marine n-3 Fatty Acids on Plasma Levels of sCD36 in Overweight Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial. Marine Drugs. 2013; 11(9):3324-3334.

Chicago/Turabian Style

Venø, Stine K.; Nielsen, Michael R.S.; Lundbye-Christensen, Søren; Schmidt, Erik B.; Handberg, Aase. 2013. "The Effect of Low-Dose Marine n-3 Fatty Acids on Plasma Levels of sCD36 in Overweight Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial." Mar. Drugs 11, no. 9: 3324-3334.

Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert